SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience (TWST) stock came under pressure after Senior Vice President of Human Resources Paula Green sold more than 39,400 shares for nearly US$2.1 million, following a strong year to date ...
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of ...
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST) (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health ...
Hosted on MSN
Twist Bioscience outlines 13–15.5% revenue growth target for 2026 as AI-driven orders accelerate
CEO Emily Leproust highlighted a record quarter with $99 million in revenue and 17% year-over-year growth, noting "our 11th quarter of consecutive growth." She stated, "For the year, we reported ...
Twist Bioscience (NASDAQ:TWST) is gearing up to announce its quarterly earnings on Monday, 2026-02-02. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST) (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector ...
1mon
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp ...
Twist Bioscience specializes in synthetic DNA production, providing gene fragments, next generation sequencing (NGS) tools, and antibody discovery platforms to research, diagnostic, pharmaceutical, ...
Hosted on MSN
Twist Bioscience outlines $435M–$440M 2026 revenue target while accelerating AI-enabled discovery investments
CEO Emily Leproust highlighted "a strong start to fiscal 2026 and extend a pattern of consistent execution, marking our 12th consecutive quarter of revenue growth." She emphasized a 24% revenue CAGR ...
Offering includes Animal Origin-Free Preps, Transfection-Grade Preps and Target Yield with turnaround time starting at four business days for Express Genes “Our new plasmid preps combine the quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results